Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
- Conditions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT01026051
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸Martin Memorial, Stuart, Florida, United States
A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 39
- Registration Number
- NCT01021891
- Locations
- 🇺🇸
Diabetes & Glandular Disease Research Assoc PA, San Antonio, Texas, United States
🇬🇧Medicines Evaluation Unit (MEU), Manchester, England, United Kingdom
🇬🇧ICON Development Solutions, Manchester, United Kingdom
Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT00934414
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Chula Vista, California, United States
A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 13
- Registration Number
- NCT00757367
- Locations
- 🇺🇸
PACT Pulmonary Associates, Phoenix, Arizona, United States
An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial
- Conditions
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2014-10-16
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 229
- Registration Number
- NCT00754624
- Locations
- 🇺🇸
Dorothy L & James E Frank Diabetes Research Institute, San Mateo, California, United States
🇺🇸Sansum Medical Research Institute, Santa Barbara, California, United States
🇺🇸Soundview Research Associates, Norwalk, Connecticut, United States
Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake
- Conditions
- Interventions
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2014-10-30
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT00747006
- Locations
- 🇺🇸
Sansum Medical Research Institute, Santa Barbara, California, United States
A 2-Month Safety Follow-Up Trial
- Conditions
- Interventions
- First Posted Date
- 2008-08-26
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 649
- Registration Number
- NCT00741429
- Locations
- 🇺🇸
Private Practice, Decatur, Georgia, United States
🇺🇸Laureate Clinical Research Group, Atlanta, Georgia, United States
🇺🇸Executive Health and Research Associates Inc, Atlanta, Georgia, United States
A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.
- Conditions
- Interventions
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT00721344
- Locations
- 🇺🇸
Charles River Clinical Services Northwest, Tacoma, Washington, United States
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
- Conditions
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2014-10-16
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 130
- Registration Number
- NCT00700622
- Locations
- 🇺🇸
AM Diabetes and Endocrinology Center, Barrtlett, Tennessee, United States
🇺🇸Diabetes Research Center -Fletcher Allen Health Care, South Burlington, Vermont, United States
🇺🇸The Whittier Institute for Diabetes Clinical Trials, La Jolla, California, United States
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.
- Conditions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2010-08-03
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 19
- Registration Number
- NCT00688090
- Locations
- 🇺🇸
H Lee Moffitt Cancer Center University of So Florida, Tampa, Florida, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States